Preparation, quality control and biodistribution of [61Cu]-doxorubicin for PET imaging

RADIOCHEMISTRY, RADIOPHARMACEUTICALS AND NUCLEAR MEDICINE

Preparation, quality control and biodistribution of [⁶¹Cu]-doxorubicin for PET imaging

JALILIAN Amir Reza，

YOUSEFNIA Hassan，

FAGHIHI Reza，

AKHLAGHI Mehdi，

ZANDI Hassan

Nuclear Science and Techniques

Vol.20, No.3

pp.157-162

Published in print 20 Jun 2009

DOI：10.13538/j.1001-8042/nst.20.157-162

32600

This work was conducted for radiolabeling of an anticancer antibiotic, i.e. doxorubicin with ⁶¹Cu for production of possible tracer used in PET oncology. ⁶¹Cu was prepared with natural zinc target and 22 MeV150 µA protons via ^natZn(p, xn)⁶¹Cu reaction with a yield of 123.2 MBq·µA^–1·h^–1. Optimization reactions were performed for pH, temperature and concentration. Biodistribution of the tracer was studied in normal and fibrosarcoma bearing mice. At the optimized conditions, ITLC showed that radiochemical purity was over 97% with a specific activity of 2.22×10³MBq ·mmol^-1·L^-1. This was kept unchanged even with presence of human serum as well as room temperature for 5 h. Biodistribution of the tracer in fibrosarcoma bearing mice demonstrated significant tumor uptake after 2 h. This tracer can be used in the detection of various tumors responding to doxorubicin chemotherapy using PET scan and/or determination of tumor therapy response to doxorubicin chemotherapy.

Copper-61DoxorubicinRadiolabelingBiodistribution

References

[1]

Jalilian A R, Mirsadeghi L, Yari-Kamrani Y, et al. J Radioanal Nucl Chem, 2007, 274: 563-568.

[2]

Rowshanfarzad P, Jalilian A R, Kyomarsi M, et al. Nukleonika, 2006, 51: 209-215.

[3]

Jager P L, de Korte M A, Lub-de Hooge M N, et al. Cancer Imag, 2005, 23: AS27-32.

[4]

Mccarthy D W, Bass L A, Cutler P D, et al. Nucl Med Biol, 1999, 26: 351-358.

[5]

Ma D F, Lu T, Overstreet D E, et al. Nucl Med Biol, 2002, 29: 91-105.

[6]

Fukumura T, Okada K, Szelecsényi F, et al. Radiochimica Acta, 2004, 92: 209-214.

[7]

Jalilian A R, Rowshanfarzad P, Sabet M. Appl Radiat Isot, 2006, 64: 337-341.

[8]

Lewis J S, Sharp T L, Laforest R, et al. J Nucl Med, 2001, 42: 655-661.

[9]

Pharmacia Company. Mithramycin(doxorubicin), drug information inlet, Millan, Italy, 2007.

[10]

Fischer J G, Tackett R L, Howerth E W, et al. J Nutr, 1992, 122: 2128-2137.

[11]

Monti E, Paracchini L, Piccinini F, et al. 1990, 25: 333-6.

[12]

Nikolis N, Methenitis C, Pneumatikakis G, et al. J Inorg Biochem, 2002, 89: 131-141.

[13]

Mizutani H, Oikawa S, Hiraku Y. Cancer Sci, 2003, 94: 686-691.

[14]

Feng M, Yang Y. Spectrochim Acta A Mol Biomol Spectrosc, 2000, 56: 581-587.

[15]

Tachibana M, Iwaizumi M, Tero-Kubota S. J Inorg Biochem, 1987, 30: 133-140.

[16]

Jalilian A R, Sabet M, Rowshanfarzad P, et al, J Radioanal Nucl Chem, 2006, 269: 147-154.

[17]

Jalilian A R, Shanesazzadeh S, Rowshanfarzad P, et al. J Nucl Sci Tech, 2008, 19(3): 159-164.

[18]

Jalilian A R, Rostampour N, Rowshanfarzad P, et al. Acta Pharm, 2009, 59: 45-55.

[19]

Katzung G A. Principles of Pharmacology, Anticancer Antibiotics, 1922.

[20]

Lugtenburg P J, Sonneveld P. Curr Oncol Rep, 2008, 10: 412-419.

[21]

Rowshanfarzad P, Sabet M, Jalilian A R, et al. Appl Radiat Isot, 2006, 64: 1563-1573.

[22]

Blann M, Bislinghoff J,

Code Alice/Livermore 91, Lawrence Livermore National Laboratory, Internal Report, UCID-19614

, 1991.

Baidu Scholar

Google Scholar

[23]

Ziegler J F, Biersack J P, Littmark U. The code of SRIM-the stopping and range of ions in matter(a software), Version 2000.XX, 2000.

[24]

Weisberg A M. Gold Plating (9th ed.), U.S.A: ASM International, 1990: 247.

[25]

Schwarzbach R, Zimmerman K, Bläuenstein P, et al. Appl Radiat Isot, 1995, 46: 329-336.

[26]

Marczenko Z. Spectrophotometric determination of elements(4th ed.), New York: John Wiley & Sons Inc, 1976: 601.

[27]

Marczenko Z. Spectrophotometric determination of elements (4th ed.). New York: John Wiley & Sons Inc, 1976: 281.

[28]

Jaaskela-Saari H A, Kairemo K J, Ramsay H A. Int J Radiat Biol, 1998, 73: 565-570.

[29]

DiGiovanni J, Rymer J, Slaga T J, et al. Carcinogenesis. 1982, 3: 371-375.

[30]

Creasey W A, McIntosh L S, Brescia T, et al. Cancer Res, 1976, 36: 216-221.